Search results for "REPLACEMENT THERAPY"

showing 10 items of 289 documents

Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts

2018

Source at https://doi.org/10.1186/s13058-018-1073-0. Licensed CC BY-NC-ND 4.0. Background: Few published breast cancer (BC) risk prediction models consider the heterogeneity of predictor variables between estrogen-receptor positive (ER+) and negative (ER-) tumors. Using data from two large cohorts, we examined whether modeling this heterogeneity could improve prediction. Methods: We built two models, for ER+ (ModelER+) and ER- tumors (ModelER-) , respectively, in 281,330 women (51% postmenopausal at recruitment) from the European Prospective Investigation into Cancer and Nutrition cohort. Discrimination (C-statistic) and calibration (the agreement between predicted and observed tumor risks)…

OncologyHORMONE-REPLACEMENT THERAPYmedicine.medical_treatmentWHI0302 clinical medicineBreast cancerRisk FactorsEstrogen receptor030212 general & internal medicineProspective StudiesProspective cohort study2. Zero hungerIncidenceHormone replacement therapy (menopause)Middle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisRisk prediction3. Good healthEuropean Prospective Investigation into Cancer and NutritionMenopausePOSTMENOPAUSAL WOMENReceptors EstrogenPLUS PROGESTIN030220 oncology & carcinogenesisCohortFemaleRisk assessmentResearch Articlemedicine.medical_specialtyMODELSAntineoplastic AgentsBreast NeoplasmsEstrògenslcsh:RC254-282Models BiologicalRisk AssessmentVALIDATIONCàncer de mamaMAMMOGRAPHY03 medical and health sciencesBreast cancerInternal medicinemedicineHumansOncology & CarcinogenesisCancer och onkologiVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762business.industryMORTALITYKirurgiProspective cohortmedicine.diseaseEstrogenVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762Cancer and OncologySurgerybusinessEPIC1112 Oncology And CarcinogenesisBody mass indexFollow-Up StudiesBreast Cancer Research : BCR
researchProduct

Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels.

2003

Objective To compare the long-term effects of oral and transdermal hormone replacement therapy (HRT) on serum homocysteine levels in postmenopausal women. Design An open, prospective, controlled study. Seventy-five healthy postmenopausal women were recruited as eligible for the study. Fifty women seeking HRT were randomized to receive continuous 17beta-estradiol, either by oral (2 mg daily; n = 25) or transdermal (50 microg daily; n = 25) administration, plus 10 mg dydrogesterone daily for 14 days of each 28-day cycle. Twenty-five women unwilling to receive hormone treatment received only calcium supplementation, representing the control group. Fasting blood samples were analyzed at baselin…

Oralmedicine.medical_specialtyAdministration CutaneouHomocysteineEstronemedicine.medical_treatmentHRTAdministration OralEstroneDydrogesteroneAdministration CutaneousGastroenterologylaw.inventionchemistry.chemical_compoundFollicle-stimulating hormoneRandomized controlled triallawReference ValuesInternal medicineMedicineHumansReference ValueProspective StudiesProspective cohort studyHomocysteineTransdermalEstradiolProgesterone Congenersbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyHormone replacement therapy (menopause)Progesterone CongenerMiddle AgedHomocysteine; HRT; TransdermalPostmenopauseProspective StudieEndocrinologychemistryDydrogesteroneDrug Therapy CombinationFemaleFollicle Stimulating HormonebusinessTransdermalmedicine.drugHumanMenopause (New York, N.Y.)
researchProduct

743 Lysosomal Storage Disorders in Non-Immunological Hydrops Fetalis - More Common than Assumed?

2012

Background Although non immunological hydrops fetalis (NIHF) is a very rare disorder, the disturbance accounts for a disproportionate share (3%) of overall mortality in the perinatal period. Lysosomal storage disorders (LSD) are only exceptionally considered to be the cause of NIHF. The reported incidence is about 1%. On the other hand, in about 18% of all cases, NIHF is classified as idiopathic. Patients and methods We report four cases of transient NIHF due to LSD and reviewed the literature for LSD associated with NIHF. Results At present, 12 different LSD are described to be associated with NIHF. The majority of reported patients already had a family history of NIHF, which had not been …

Pathologymedicine.medical_specialtyFetusPediatricsbusiness.industryGenetic counselingIncidence (epidemiology)Lysosomal storage disordersEnzyme replacement therapymedicine.diseaseHydrops fetalisPediatrics Perinatology and Child HealthEtiologyMedicineFamily historybusinessArchives of Disease in Childhood
researchProduct

Early access experience with VPRIV®: Recommendations for ‘core data’ collection

2011

Pathologymedicine.medical_specialtyGaucher DiseaseData collectionProcess managementbusiness.industryData CollectionCell BiologyHematologyRecombinant ProteinsCell LineCore (game theory)Practice Guidelines as TopicGlucosylceramidaseHumansMolecular MedicineMedicineEnzyme Replacement TherapybusinessMolecular BiologyBlood Cells, Molecules, and Diseases
researchProduct

Evaluation of the potential therapeutic effects of a double-stranded RNA mimic complexed with polycations in an experimental mouse model of endometri…

2015

Objective To assess the therapeutic potential of polyinosine-polycytidylic acid, a double-stranded RNA molecule with selective proapoptotic and antiangiogenic activity, complexed with polyethyleneimine (pIC PEI ) in treating endometriosis. Design A heterologous mouse model of endometriosis was created by injecting human endometrial fragments into the peritoneum. Endometrial fragments were engineered to express the fluorescent protein mCherry as a reporter to monitor status over the course of the 4-week study. Setting University-affiliated infertility center. Animal(s) Ovariectomized and hormone-replaced nude mice (n = 30) injected with fluorescent-labeled human endometrial fragments at 4–6 …

Pathologymedicine.medical_specialtyTime FactorsOvariectomyEndometriosisEndometriosisHeterologousMice NudeAngiogenesis InhibitorsApoptosisEndothelial Growth FactorsBiologyEndometriumPeptides CyclicNeovascularizationEndometriumPeritoneumGenes ReportermedicineAnimalsHumansPolyethyleneimineCell ProliferationNeovascularization PathologicCell growthEstrogen Replacement TherapyObstetrics and Gynecologymedicine.diseaseMolecular biologyDisease Models AnimalLuminescent Proteinsmedicine.anatomical_structurePoly I-CReproductive MedicineApoptosisHeterograftsFemalemedicine.symptommCherryFertility and sterility
researchProduct

Angiokeratoma: decision-making aid for the diagnosis of Fabry disease

2012

Isolated angiokeratomas are common benign cutaneous lesions, generally deemed unworthy of further investigation. In contrast, diffuse angiokeratomas should alert the physician to a possible diagnosis of Fabry disease, a rare X-linked lysosomal storage disorder, characterized by α-galactosidase deficiency. Glycosphingolipids accumulate in cells throughout the body resulting in progressive multi-organ failure. Difficulties are encountered when trying to interpret the significance of angiokeratomas because they may also occur in other lysosomal storage disorders and rarely in an isolated manner in Fabry disease. We present an algorithm for the classification of angiokeratomas which might prove…

Pathologymedicine.medical_specialtymedicine.diagnostic_testbusiness.industryVascular diseaseDermatologyDiseaseEnzyme replacement therapymedicine.diseaseFabry's diseaseFabry diseaseDermatologyAngiokeratomaSkin biopsyMedicineFamily historybusinessBritish Journal of Dermatology
researchProduct

Methods for a prompt and reliable laboratory diagnosis of Pompe disease : report from an international consensus meeting

2008

Pompe disease is an autosomal recessive disorder of glycogen metabolism caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). It presents at any age, with variable rates of progression ranging from a rapidly progressive course, often fatal by one-year of age, to a more slowly, but nevertheless relentlessly progressive course, resulting in significant morbidity and premature mortality. In infants, early initiation of enzyme replacement therapy is needed to gain the maximum therapeutic benefit, underscoring the need for early diagnosis. Several new methods for measuring GAA activity have been developed. The Pompe Disease Diagnostic Working Group met to review data gener…

Pediatricsmedicine.medical_specialtyEndocrinology Diabetes and MetabolismDiseaseBiochemistryEarly initiationchemistry.chemical_compoundEndocrinologyInternal medicineGlycogen storage disease type IIGeneticsmedicineHumansMolecular BiologyAcarboseMuscle biopsyGlycogenmedicine.diagnostic_testClinical Laboratory TechniquesGlycogen Storage Disease Type IIbusiness.industryInfantEnzyme replacement therapymedicine.diseasePompe disease; laboratory diagnosisEndocrinologychemistryAcid alpha-glucosidaseGlucan 14-alpha-Glucosidasebusinessmedicine.drug
researchProduct

Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy

2017

Factor VII deficiency is the most common among rare inherited autosomal recessive bleeding disorders, and is a chameleon disease due to the lack of a direct correlation between plasma levels of coagulation Factor VII and bleeding manifestations. Clinical phenotypes range from asymptomatic condition—even in homozygous subjects—to severe life-threatening bleedings (central nervous system, gastrointestinal bleeding). Prediction of bleeding risk is thus based on multiple parameters that challenge disease management. Spontaneous or surgical bleedings require accurate treatment schedules, and patients at high risk of severe hemorrhages may need prophylaxis from childhood onwards. The aim of the c…

Pediatricsmedicine.medical_specialtyGastrointestinal bleedingPathologyGenotypediagnosisInherited Factor VII derficiencyDiseaseReview030204 cardiovascular system & hematologyAsymptomatic03 medical and health sciences0302 clinical medicineRepalcement Therapyreplacement therapyGenotypemedicineFactor VII deficiencyClinical phenotypebusiness.industryBleedingGeneral MedicinePlasma levelsmedicine.diseasePhenotypeinherited Factor VII deficiencymedicine.symptombusiness030215 immunology
researchProduct

Age at symptom onset, diagnosis, and enzyme replacement therapy (ERT) initiation among family members with mucopolysaccharidosis II (Hunter Syndrome)…

2013

Pediatricsmedicine.medical_specialtyMucopolysaccharidosis IIbusiness.industryEndocrinology Diabetes and MetabolismHunter syndromeEnzyme replacement therapymedicine.diseaseBiochemistrySurgeryEndocrinologyGeneticsmedicineSymptom onsetbusinessMolecular BiologyMolecular Genetics and Metabolism
researchProduct

Diagnostik und Therapie des Morbus Pompe im Kindesalter

2020

Pompe disease is a rare metabolic myopathy caused by deficiency of lysosomal α-glucosidase. Reduced enzyme activity results in abnormal intra- and extralysosomal glycogen deposition as well as impaired cellular function and autophagy. Age at manifestation and severity of disease depend on residual enzyme activity. Enzyme replacement therapy (ERT) is available since 2006. In infantile onset Pompe disease, the most severe form, markedly prolonged survival has resulted in a new phenotype with symptoms and problems not encountered previously. In addition, it became apparent that antibody formation against the recombinant human enzyme may adversely affect the response to ERT. This review summari…

Pediatricsmedicine.medical_specialtybiologybusiness.industryAutophagy030232 urology & nephrologyMedizinGlycogen deposition610 Medicine & healthDiseaseMetabolic myopathyEnzyme replacement therapymedicine.diseaseEnzyme assay03 medical and health sciences0302 clinical medicine10036 Medical Clinic030225 pediatricsPediatrics Perinatology and Child HealthGlycogen storage disease type IImedicinebiology.proteinbusinessAntibody formation
researchProduct